<p>Stress incontinence and overactive bladder are disorders with a common symptom, urinary incontinence, which is a serious medical and social handicap. Several neurotransmitters regulate the function of the lower urinary tract, including noradrenaline, acetylcholine, and serotonin.</p><p>The present study is part of the search for pharmacological incontinence drugs. The aims of this thesis were to improve the existing pharmacological treatments of urinary incontinence and to look for alternative treatments: i) an α<sub>1</sub>-adrenergic agonist that preferentially affects urethral over blood pressure was tested <i>in vivo</i>; ii) a modified cystometry model was developed for screening of muscarinic antagonists, by construction of a complete dose-response curve in each individual animal; iii) a new muscarinic antagonist, PNU-171990, was pharmacologically characterized <i>in vitro</i> and <i>in vivo</i>; iv) functional differences of the isomers of the muscarinic agonist BM-5 were characterized in the urinary bladder and ileum, <i>in vitro</i> and <i>in vivo</i>; v) the role of serotonin 5-HT<sub>2A</sub>, 5-HT<sub>3</sub> and 5-HT<sub>4</sub> receptors were characterized on urinary bladder contractions <i>in vivo</i>.</p><p>In the search for urethra selective compounds, the α<sub>1</sub>-adrenoceptors agonists phenylephrine and phenylpropanolamine selectively enhanced blood pressure as compared to the urethral pressure in rabbit. This is in contrast to the effect of oxymetazoline and NS-49. Muscarinic antagonists produced a dose-dependent inhibition of the volume-induced micturition pressure in the rat. PNU-171990, a non-selective muscarinic antagonist, revealed selectivity for urinary bladder pressure over salivation (P<0.05). (R)-BM-5 induced bladder contraction and saliva secretion in cats. The selective serotonin 5-HT<sub>2A</sub> and 5-HT<sub>3</sub> receptor antagonists, ketanserin and tropisetron, both inhibited the effect of chemically induced bladder contraction in the anaesthetized cat.</p><p>In conclusion, an urethral-selective α<sub>1A</sub>-adrenoceptor agonist may be a good treatment of stress incontinence. A bladder-selective competitive muscarinic antagonist is considered a good pharmacotherapy for overactive bladder. In addition, the 5-HT<sub>2A</sub> and 5-HT<sub>3 </sub>receptor antagonist may improve lower urinary tract symptoms.</p>
| Identifer | oai:union.ndltd.org:UPSALLA/oai:DiVA.org:uu-1927 |
| Date | January 2002 |
| Creators | Modiri, Ali-Reza |
| Publisher | Uppsala University, Department of Neuroscience, Uppsala : Acta Universitatis Upsaliensis |
| Source Sets | DiVA Archive at Upsalla University |
| Language | English |
| Detected Language | English |
| Type | Doctoral thesis, comprehensive summary, text |
| Relation | Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, 0282-7476 ; 1137 |
Page generated in 0.0017 seconds